Familial HLH is a success story in modern medicine. Initially a disease that was largely unknown and fatal, it is now understood on a molecular level and is curable. Moreover, HLH is an archetype of ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

MAY 9, 2025, NEW YORK – A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies. Led by Ludwig ...

Cancer immunotherapy has revolutionized treatment for many patients, but significant challenges remain in predicting who will respond to these life-saving treatments. A new comprehensive review ...

Therapeutically targeting the CALR/CD47 pathway in MPN to reactivate natural immunosurveillance mechanisms within the body to enhance treatment outcomes. This is an ASCO Meeting Abstract from the ASCO ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

When immune cells strike, precision is everything. New research reveals how natural killer and T cells orchestrate the release of toxic granules—microscopic packages that destroy virus-infected or ...

Immunostimulant therapy using agonistic cytokines or activating antibodies has been associated with off-target side effects, failure to preferentially activate cytotoxic lymphocytes (CTLs) over ...

From eye color to whether cilantro tastes like soap, genetic variability influences many factors in a person’s life. These inherited differences can also determine a person’s risk of developing a ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies. Led by Ludwig Princeton's Lydia Lynch ...